MIP-3 alpha/CCL20 蛋白, Mouse

MIP-3 alpha/CCL20 Protein, Mouse is a CC chemokine that attracts lymphocytes and mild neutrophils by binding to and acting on the chemokine receptor CCR6. It induces intracellular calcium mobilization and mediates cancer, various autoimmune diseases, and antimicrobial effects. MIP-3 alpha/CCL20 Protein, Mouse  is a recombinant mouse CCL20 (A28-M97) expressed by E. coli^[1].

CCL20，也称为巨噬细胞炎症蛋白3α（MIP-3-α）和肝激活调节趋化因子（LARC），是属于CC趋化因子家族的一种小细胞因子，位于人类基因组中的2号染色体上。它在胸腺、睾丸、前列腺和肠道中表达水平较低。CCL20 与 CCR6 结合并充当趋化因子受体，并与 CCR6 协同抑制 CD8 T 细胞的功能。CCL20 具有抗菌活性，与炎症性肠病、类风湿性关节炎、牛皮癣等自身免疫性疾病以及肿瘤疾病有关。它可以诱导Treg细胞侵入肿瘤组织，募集树突状细胞促进免疫抑制，并诱导内皮细胞增殖和新内膜形成^[1][2]。

CCL20 is preferentially released into the apical chamber in polarized BALB/c mouse uterine epithelial cells. In contrast, in rats, it is preferentially released into the basolateral compartment^[3].

CCL20 (s.c., 0.5 μg in 100 μL 1×PBS, every week, 21 days or 28 days) recruits a large number of GFP+ Treg cells to the tumor, and the tumor size of the mice is also significantly increased compared to the PBS control in B6.Cg-Foxp3 ^tm2Tch/J mice^[4].

Full biological activity determined by a chemotaxis bioassay using human CCR6 transfected murine BaF3 cells is in a concentration range of 0.1-10 ng/ml.

Mouse

E. coli

Tag Free

O89093 (A28-M97)

20297  [NCBI]

ASNYDCCLSYIQTPLPSRAIVGFTRQMADEACDINAIIFHTKKRKSVCADPKQNWVKRAVNLLSLRVKKM

Approximately 8.0 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized after extensive dialysis against PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Louis Boafo Kwantwi, et al. Multifaceted roles of CCL20 (C-C motif chemokine ligand 20): mechanisms and communication networks in breast cancer progression. Bioengineered. 2021 Dec;12(1):6923-6934.  [Content Brief]

  [2]. Skovdahl HK, et al. C-C Motif Ligand 20 (CCL20) and C-C Motif Chemokine Receptor 6 (CCR6) in Human Peripheral Blood Mononuclear Cells: Dysregulated in Ulcerative Colitis and a Potential Role for CCL20 in IL-1β Release. Int J Mol Sci. 2018 Oct 20;19(10).  [Content Brief]

  [3]. M Baba, et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem. 1997 Jun 6;272(23):14893-8.  [Content Brief]

  [4]. Benkheil M, et al. CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer. Exp Cell Res. 2018 Nov 15;372(2):168-177.  [Content Brief]

  [5]. Gisela Soboll, et al. Effect of oestradiol on PAMP-mediated CCL20/MIP-3 alpha production by mouse uterine epithelial cells in culture. Immunology. 2006 Jun;118(2):185-94.  [Content Brief]

  [6]. Jinlin Liu, et al. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One. 2011 Apr 29;6(4):e19495.  [Content Brief]